The headline reads as positive (76% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › RMD
Resmed Inc (RMD) stock analysis
WEAK BUY 17% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Resmed Inc (RMD) WEAK BUY with 17% confidence at a price of $252.83. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$252.83
Technical picture
The 14-day RSI is 82, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (1.3x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $275.42 and the swing low is $179.75; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.35, which looks reasonably priced for its growth.
The company reports a profit margin of 26.9% and revenue growth of +8.6%.
In its latest quarter it earned $2.91 per share, which beat the $2.67 analysts expected, with revenue +8.6% year over year.
Wall Street's average rating is 2.3 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $251.52.
Trade plan from the model
The model's long / bullish plan uses an entry near $252.83, a target of $260.07 (+2.9%) and a stop-loss at $241.60 (-4.4%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 9, 2026 whatever the price does.
Entry$252.83
Target$260.07
Stop-loss$241.60
Reassess byNov 9, 2026
Research notes
ResMed’s bull case is strong execution in sleep-apnea devices and masks: fiscal Q1 2027 revenue rose 6% to $1.415 billion, adjusted EPS increased 14% to $2.91, and margins expanded, while its dominant U.S. market position and AirTouch F40 launch offer further growth. The bear case centers on valuation and competitive risk, including potential Philips Respironics re-entry, emerging rivals, GLP-1 drugs’ possible impact on sleep-apnea demand, and the Astral corrective action weighing on FY2027. The major recent catalyst was the October 29 earnings beat—EPS exceeded consensus by $0.24—and management maintained full-year adjusted EPS guidance of $12.00–$12.25. With shares near $253, the roughly $243 average analyst target implies limited near-term upside despite the solid operating momentum.
The model's one-paragraph read
Leans BUY — composite score +0.17 (WEAK BUY). Technicals: RSI 81.85, MACD bullish, price above SMA50. Fundamentals: PEG 1.35, margin 26.9%, revenue growth 8.6%. Financial results: YoY revenue +8.6%, last EPS surprise +9.0%. Smart Money Concepts: ranging / no clear structure. FinGPT news read: neutral. Internet research: ResMed’s **bull case** is strong execution in sleep-apnea devices and masks: fiscal Q1 2027 revenue rose 6% to $1.415 billion, adjusted EPS increased 14% to $2.91, and margins expanded, while its dominant U.S. market position and AirTouch F40 launch offer further growth. The **bear case** centers on valuation and competitive risk, including potential Philips Respironics re-entry, emerging rivals, GLP-1 drugs’ possible impact on sleep-apnea demand, and the Astral corrective action weighing on FY2027. The major recent catalyst was the October 29 earnings beat—EPS exceeded consensus by $0.24—and management maintained full-year adjusted EPS guidance of $12.00–$12.25. With shares near $253, the roughly $243 average analyst target implies limited near-term upside despite the solid operating momentum. Suggested levels: entry $252.83, target $260.07, stop-loss $241.6, exit by 2026-11-09 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for RMD
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 17% | $252.83 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on RMD
Oct 30, 2026 · ResMed Beats On Margin And Buybacks, But Unchanged Guidance Signals A Steady Rather Than Accelerating Year
- Oct 30, 2026: ResMed Beats On Margin And Buybacks, But Unchanged Guidance Signals A Steady Rather Than Accelerating Year (Earnings Whispers)
Frequently asked questions
Is RMD a buy right now?
As of Oct 30, 2026, our automated model rates Resmed Inc (RMD) WEAK BUY with 17% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for RMD?
The model's most recent plan targets $260.07 with a stop-loss at $241.60, from an entry near $252.83.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.